Unleash the power of RNAa technology to turn on nearly any beneficial genes

Ractigen Therapeutics's platform is based on a technology called RNAa (RNA activation) that utilizes small RNA duplexes to specifically target and up-regulate therapeutic genes. RNAa represents one of the few available technologies that could be translated into the clinic to treat disease by stimulating the production of endogenous genes. RNAa holds great promise for treating a wide variety of diseases including those undruggable by conventional therapies. The therapeutic benefits of RNAa have been demonstrated in a number of preclinical studies carried out in different disease models.


Ractigen Therapeutics is an early-stage biopharmaceutical company committed to bringing to market first-in-class products for the treatment of a wide variety of diseases, with a focus on cancer and debilitating genetic diseases. Founded in 2016, Ractigen is developing a rich pipeline of candidates with our most advanced product candidate entering IND-enabling development.

More infos
Long Cheng Li

Long-Cheng Li, M.D.

Co-Founder, President & CEO
Moorim Kang

Moo Rim Kang, Ph.D.

Vice President, CTO

News & Events

Wednesday, July 11, 2018  News

Delegation from Nantong University Medical School visits Ractigen

[July 11, 2018] Today, a 5-member delegation, led by the dean Professor Fei Sun, from Nantong University Medical School paid a visit to Ractigen and Rudong Life and Health Industry Park. After touring the company building and getting a taste of the overall work environment, the group retired to...